<DOC>
	<DOCNO>NCT01079780</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab ramucirumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Cetuximab ramucirumab may also stop growth colorectal cancer block blood flow tumor . It yet know whether give cetuximab irinotecan hydrochloride together effective without ramucirumab treat colorectal cancer . PURPOSE : This randomized phase II trial study side effect well give cetuximab irinotecan hydrochloride without ramucirumab work treat patient advanced colorectal cancer progressive disease treatment bevacizumab-containing chemotherapy .</brief_summary>
	<brief_title>Irinotecan Hydrochloride Cetuximab With Without Ramucirumab Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate progression-free survival patient advance K-ras wild-type colorectal cancer , follow progression bevacizumab-contained chemotherapy , treat irinotecan hydrochloride cetuximab versus without ramucirumab second-line therapy . - To evaluate response rate patient treat regimen . - To evaluate grade 3-4 toxicity rate regimens patient . - To evaluate overall suvival patient treat regimen . OUTLINE : This multicenter , randomize study . Patients stratify accord performance status ( 0 vs 1 ) , discontinuation oxaliplatin disease progression ( yes v ) , time disease progression since last treatment ( ≤ 6 month vs &gt; 6 month ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive cetuximab IV 60-120 minute irinotecan hydrochloride 60-90 minute day 1 . - Arm II : Patients receive ramucirumab IV 60 minute day 1 cetuximab irinotecan hydrochloride arm I . In arm , course repeat every 14 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum , include : Advanced disease Histologic variants adenocarcinoma allow Kras wild type base either primary metastatic tumor No mutate type Measurable disease Must receive prior firstline therapy comprise oxaliplatinbased fluoropyrimidinecontaining chemotherapy bevacizumab metastatic colorectal cancer No 42 day since confirmed disease progression No brain CNS metastases PATIENT CHARACTERISTICS : Performance status 01 ANC ≥ 1,500/μL Platelet count ≥ 75,000/μL Hemoglobin ≥ 9 g/dL Serum creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance ≥ 40 mL/min Urine protein ≤ 1+ dipstick routine urinalysis ( ≥ 2+ , 24hour urine collection must demonstrate &lt; 1,000 mg protein ) Total bilirubin ≤ 2.0 mg/dL AST ALT ≤ 3.0 time ULN ( 5.0 time ULN patient liver metastasis ) INR ≤ 1.6 ( ≤ 3.0 patient warfarin active bleeding [ i.e. , bleed within past 14 day ] ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy No clinically significant ( equivalent NCI CTCAE grade 34 ) bleeding episode within past 3 month None follow : Active infection Symptomatic congestive heart failure Unstable angina pectoris Symptomatic poorly control cardiac arrhythmia Uncontrolled thrombotic hemorrhagic disorder No uncontrolled poorly control hypertension despite standard medical management ( e.g. , consistently systolic BP &gt; 160 mm Hg diastolic BP &gt; 90 mm Hg ) No acute arterial thrombotic event within past 6 month , include cerebrovascular accident , transient ischemic attack , myocardial infarction , unstable angina No cancer require therapy within past 3 year except situ carcinoma nonmelanoma skin cancer No acute subacute intestinal obstruction No history inflammatory bowel disease require pharmacological and/or surgical intervention within past 12 month No know allergy treatment component PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 28 day 90 day since prior bevacizumab No prior therapy drug oxaliplatin fluoropyrimidine plus bevacizumab colorectal cancer No major surgery within past 28 day No subcutaneous venous access device placement within past 7 day Concurrent stable dose oral anticoagulant lowmolecular weight heparin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>mucinous adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>signet ring adenocarcinoma colon</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>mucinous adenocarcinoma rectum</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>signet ring adenocarcinoma rectum</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>